Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Medical News and Perspectives
September 12, 2007

MI Risks Linked to Rosiglitazone

JAMA. 2007;298(10):1149-1151. doi:10.1001/jama.298.10.1149

Recent reports and discussions examining potential cardiovascular adverse effects of the diabetes drug rosiglitazone have left many clinicians uncertain about whether to prescribe the drug for their patients. A meta-analysis suggested that the drug was associated with a significantly increased risk of myocardial infarction among patients with type 2 diabetes (Nissen SE and Wolski K. N Engl J Med. 2007;356[24]:2457-2471), while findings from an unplanned interim analysis of data from an ongoing clinical trial were inconclusive (Home PD et al. N Engl J Med. doi:10.1056/NEJMoa073394 [published online ahead of issue June 5, 2007]).

First Page Preview View Large
First page PDF preview
First page PDF preview